WuXi BioLogics wins Adagene antibody therapeutics contract

By Flora Southey

- Last updated on GMT

WuXi BioLogics will develop and manufacture Adagene’s antibody therapeutics for the Chinese market before expanding globally.

The strategic collaboration will see the Hong-Kong-headquartered contract development and manufacturing organisation (CDMO) make antigen-focused therapies.

“This collaboration is expected to introduce the world-class life-saving biologics to the Chinese market, and then benefit patients around the world,” ​said WuXi BioLogics CEO Chris Chen in a statement​.

The antibody therapeutics will be developed at WuXi BioLogics’ biologics development facility​ in Shanghai, and made at its manufacturing site​ in WuXi City, spokesperson Lia Jia told us.

WuXi BioLogics’ manufacturing plant – located 100km west of Shanghai – consists of two 1,000L single-use bioreactors, and 14 2,000L fed-batch cell culture disposable vessles supplied​ by vendor Thermo Fisher.

Three months ago the CDMO announced​ it had initiated current good manufacturing practice (cGMP) production at the site.

At the time, WuXi BioLogics told told Biopharma-Reporter the facility’s 30,000L capacity was already “mostly filled.”

Related news

Show more

Related products

show more

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...

Related suppliers